Osteomodulin (OMD) as A Potential Prognostic Marker of GastricCancer and A New Immunotherapy Target
- Author:
Feng PAN
1
;
Jia-Qi NIE
1
;
Xu-Dong ZHANG
1
;
Xiao-Ning LI
1
;
Hai-Kang CUI
1
;
Lan YANG
1
;
Wen-Jie ZHANG
1
;
Hong-Yun PENG
2
;
Feng PAN
3
;
Jia-Qi NIE
3
;
Xu-Dong ZHANG
3
;
Xiao-Ning LI
3
;
Hai-Kang CUI
3
;
Lan YANG
3
;
Wen-Jie ZHANG
3
Author Information
- Publication Type:Journal Article
- Keywords: bioinformatics analysis; gastric cancer; immunecell infiltration; osteomodulin(OMD); survival prognosis
- From: Chinese Journal of Biochemistry and Molecular Biology 2022;38(1):97-107
- CountryChina
- Language:Chinese
- Abstract: Preoperative detection of biomarkers that can predict postoperative survival of gastric cancer patients has important implications for surgical procedures, postoperative chemoradiotherapy and followup. Using multi-center cancer database and online analysis and verifying by qRT-PCR and Western blotting, we found that Osteomodulin (OMD) was highly expressed in gastric cancer tissues (P =0. 015) and could affect the survival of gastric cancer patients (P < 0. 001) and can be detected preoperatively to evaluate the prognosis of gastric cancer patients. The mRNA expression of OMD was significantly correlated with age (P = 0. 034), Lauren typing (P < 0. 001) and clinical stage (P =0. 001) of gastric cancer patients. It also associated with a variety of immune cells (dendritic cellsresting, eosinophils) and the immune checkpoint regulator ENTPD1 (rho = 0. 634, P < 0. 001) and chemokine CXCL12 (rho = 0. 625, P < 0. 001), which affects the occurrence and development of gastriccancer through the immune microenvironment. Therefore, OMD may become a clinically feasible prognostic biomarker of gastric cancer and a new target for immunotherapy.
